# Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

> **NCT05203276** · PHASE2 · UNKNOWN · sponsor: **The First People's Hospital of Lianyungang** · enrollment: 40 (estimated)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** Envafolimab
- **DRUG:** Endostar

## Key facts

- **NCT ID:** NCT05203276
- **Lead sponsor:** The First People's Hospital of Lianyungang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203276, "Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05203276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*